<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00938132</url>
  </required_header>
  <id_info>
    <org_study_id>A657-BR-CT-108</org_study_id>
    <nct_id>NCT00938132</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers</brief_title>
  <official_title>A Clinical Trial to Evaluate the Effect of Fimarsartan on Pharmacodynamics, Pharmacokinetics, and the Safety of Warfarin in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boryung Pharmaceutical Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boryung Pharmaceutical Co., Ltd</source>
  <brief_summary>
    <textblock>
      To evaluate the effect of Fimarsartan on pharmacodynamics, pharmacokinetics, and the safety
      of warfarin in healthy male volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INR AUC, INRmax, INRtmax</measure>
    <time_frame>pre-dose, 6, 12, 24, 36, 48, 72, 96, 120, 144 h post-dose on 1 d, 11 d</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUClast, AUCinf, Cmax ,Tmax, CL/F of S-warfarin and R-warfarin</measure>
    <time_frame>pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 24, 36, 48, 72, 96, 120, 144 h post-dose on 1 d, 11 d</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>Fimasartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fimasartan, warfarin</intervention_name>
    <description>Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)</description>
    <arm_group_label>Fimasartan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age: 20 - 40 years

          -  sex: male

          -  body weight: greater than 55 kg

          -  written informed consent

        Exclusion Criteria:

          -  known allergy to Fimasartan and warfarin

          -  existing cardiac or hematological diseases

          -  existing hepatic and renal diseases

          -  existing gastrointestinal diseases

          -  acute or chronic diseases which could affect drug absorption or metabolism history of
             any serious psychological disorder

          -  positive drug or alcohol screening

          -  smokers of 10 or more cigarettes per day 3 month ago

          -  participation in a clinical trial during the last 2 months prior to the start of the
             study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 10, 2009</study_first_submitted>
  <study_first_submitted_qc>July 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 13, 2009</study_first_posted>
  <last_update_submitted>October 7, 2009</last_update_submitted>
  <last_update_submitted_qc>October 7, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 8, 2009</last_update_posted>
  <responsible_party>
    <name_title>Choi, Director</name_title>
    <organization>Boryung Pharm Co., Inc.</organization>
  </responsible_party>
  <keyword>fimasartan</keyword>
  <keyword>drug interaction</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

